Reports
Sale
Global Tumor Ablation Market Size, Share, Trends, Analysis: By Technology: Radiofrequency Ablation, Microwave Ablation, Cryoablation, HIFU, Others; By Type: Surgical Ablation, Percutaneous Ablation; By Application: Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Others; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Tumor Ablation Market Outlook
The global tumor ablation market size was valued at USD 1.9 billion in 2023 driven by the rising prevalence and incidence of cancer across the globe. The market is expected to grow at a CAGR of 14.2% during the forecast period of 2024-2032, with the values likely to rise from USD 2.2 billion in 2024 to USD 6.3 billion by 2032.
Key Takeaways
- According to the American Cancer Society Statistics, it is estimated that 2,001,140 new cases and 611,720 cancer mortality are projected to occur in the United States in 2024.
- In March 2024, Medtronic received United States FDA 510(k) approval for OsteoCool 2.0, an ablation system designed to treat benign bone tumors.
- Growing preference for minimally invasive procedures is expected to fuel the tumor ablation market value in the forecast period.
Tumour ablation is a minimally invasive procedure commonly employed to treat tumors of the kidney, liver, bone, and lung. It is a promising alternative for patients with failed radiotherapy or chemotherapy. This technique generally uses thermal energy to heat or cool the targeted tissue to cytotoxic levels, resulting in tissue necrosis. The technical success and minimally invasive nature have fuelled its clinical relevance which is expected to drive market growth in coming years.
Major factors propelling the market expansion are the growing incidence and prevalence of cancers, continuous technological innovation in the field of tumor ablation, and the surge in research and development activities. The market landscape is likely to be positively influenced by the rising investment from the public and private sectors to foster the development of tumor ablation procedures along with the heightened public awareness related to the benefits of the technique. Moreover, the tumor ablation market demand is fuelled by the rising inclination of patients towards minimally invasive alternatives for cancer treatment.
Global Tumor Ablation Market Trends and Developments
Growing adoption of image-guided ablation, expanding applications of tumor ablation, heightened patient awareness, and the surge in regulatory approvals comprise some of the key trends and developments in the market.
| Date | Company | Event |
| March 2024 | Medtronic plc | The company received the United States Food and Drug Administration (FDA) 510(k) approval for OsteoCool 2.0, a bone tumor ablation system to treat benign bone tumors and painful bone metastases. |
| September 2023 | Techsomed | Techsomed’s ablation treatment planning software VisAble.IO was granted 510(k) clearance by the FDA. The software integrated with artificial intelligence (AI) offers a three-dimensional (3D) view of the ablation target, marking an innovation in image-guided ablation therapy. |
| August 2023 | Brain Navi Biotechnology Co., Ltd. | Brain Navi demonstrated its NaoTrac neurosurgical navigation robot and KrystoLens single-use neuro-endoscope at several conferences. NaoTrac facilitated non-invasive patient registration in two minutes while supporting neurological procedures such as tumour ablation and biopsy. |
| June 2023 | Baird Medical | Baird Medical, a Chinese corporation specializing in microwave ablation medical devices, signed a definitive agreement to merge with ExcelFin Acquisition, forming Baird Medical Investment Holdings upon deal completion. With a minimum of USD 15 million closing cash condition, the merged company is projected to hold a value of USD 370 million. |
| Key Trends | Impact |
| Growing Adoption of Image-Guided Ablation | The integration of imaging technologies (such as CT, MRI, and ultrasound) with ablation procedures not only improves the precision of tumor targeting but also minimizes damage to surrounding tissues. This advancement increases the success rates of ablation therapies and is anticipated to aid in boosting the tumor ablation market share. |
| Expanding Applications of Tumor Ablation | Research and clinical trials are actively exploring new applications for tumor ablation. This enabled the extension of its use beyond liver cancer to include kidney, lung, bone, and other types of tumors. This diversification of applications is likely to augment market demand. |
| Heightened Patient Awareness | Increased awareness among patients regarding the benefits of tumor ablation, such as reduced treatment times and lower recurrence rates, are leading to higher market demand. |
| Surge in Regulatory Approvals | The evolving regulatory support and favorable reimbursement policies for ablation procedures are positively impacting the market size. The recent surge in approvals of new procedures is projected to increase the accessibility of treatment in the market. |
Global Tumor Ablation Market Analysis
The market is driven by the rising prevalence and incidence of cancer which necessitates the development of effective treatment interventions for the huge patient base. The global burden of cancer is primarily contributed by the rise in the geriatric population and increased exposure to risk factors. With estimates predicting more than 35 million new cancer cases by 2050 , the tumor ablation market value is expected to witness significant growth in the forecast period.
One of the major market trends is the rapid technological advancement in the field of tumor ablation, encouraged by investments from the key market players. Moreover, the robust financial support from the government is helping to sustain the ongoing research initiatives aimed at improving patient outcomes via innovative tumor ablation procedures. Moreover, the inclination of patients for less invasive treatment options is a significant trend accelerating market growth.
Global Tumor Ablation Market Segmentation
“Global Tumor Ablation Market Report and Forecast 2024-2032” offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Technology | Radiofrequency Ablation, Microwave Ablation, Cryoablation, HIFU, Others |
| Type | Surgical Ablation, Percutaneous Ablation, Laparoscopic Ablation |
| Application | Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Bone Cancer |
| End User | Hospitals, Oncology Centers, Others |
| Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
By technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, and high-intensity focused ultrasound (HIFU), among others. Each technology type offers different mechanisms for destroying cancerous cells. HIFU is the only non-invasive technique among all ablation modalities although it carries several limitations. With technological advancements, HIFU is poised to emerge as an attractive treatment alternative in coming years.
In terms of type, tumor ablation procedures can be categorized as surgical ablation, percutaneous ablation, and laparoscopic ablation. This market segment illustrates different approaches to accessing and treating tumors.
The tumor ablation market share is projected to grow with its increasing application multiple domains. Common application areas include kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, bone cancer, and other tumor types. This segment reflects the clinical relevance of the technique in treating a wide range of oncological conditions.
End-users of the market are hospitals, oncology centers, and other healthcare facilities. The end users perform tumor ablation procedures as part of cancer treatment regimens.
The market report offers insights into the major regional markets such as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Regional disparities exist in the markets, which can be attributed to a myriad of factors such as healthcare infrastructure, prevalence of cancer, and the presence of key market players.
Competitive Landscape
The key market players are contributing to the tumor ablation market growth through mergers and acquisitions initiatives, innovative product launches, continuous research, and development efforts, and penetration of their offerings in the international markets.
| Company | Year Founded | Headquarters | Products/Services |
| Medtronic PLC | 1949 | Dublin, Ireland | Offers a range of ablation products, including radiofrequency ablation systems and thermosphere ablation systems. |
| Boston Scientific Corporation | 1979 | Marlborough, Massachusetts, USA | Provides various ablation solutions, including cryoablation and radiofrequency ablation (RFA). |
| Johnson & Johnson | 1886 | New Brunswick, New Jersey, USA | Through its subsidiary, Ethicon offers microwave ablation technology among other medical devices and pharmaceuticals. |
| AngioDynamics | 1988 | Latham, New York, USA | Specializes in image-guided, minimally invasive therapies, including NanoKnife for irreversible electroporation, and offers microwave and radiofrequency ablation products. |
Other key market players include EDP TMS, Mermaid Medical, CONMED Corporation, Sonablate Corporation, Integra Life Science Holding Corporation, Smith & Nephew PLC, and Olympus Corporation, among others.
Global Tumor Ablation Market Analysis by Region
North America has a significant share of the market segment, which can be attributed to the growing cancer burden in the region and the growing demand for novel treatment interventions. In addition, increasing geriatric population, product launches, and vigorous research and development initiatives are expected to bolster the market growth in the forecast period.
Europe has a substantial market value, supported by the presence of premium research institutes and key market leaders. Moreover, the advanced healthcare system in the region facilitates greater accessibility to innovative tumor ablation techniques, which is likely to drive market growth in the region.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Type |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Tumor Ablation Market Overview
3.1 Global Tumor Ablation Market Historical Value (2017-2023)
3.2 Global Tumor Ablation Market Forecast Value (2024-2032)
4 Global Tumor Ablation Market Landscape*
4.1 Global Tumor Ablation: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Tumor Ablation: Product Landscape
4.2.1 Analysis by Technology
4.2.2 Analysis by Type
4.2.3 Analysis by Application
5 Global Tumor Ablation Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Tumor Ablation Market Segmentation (2017-2032)
6.1 Global Tumor Ablation Market (2017-2032) by Technology
6.1.1 Market Overview
6.1.2 Radiofrequency Ablation
6.1.3 Microwave Ablation
6.1.4 Cryoablation
6.1.5 HIFU
6.1.6 Others
6.2 Global Tumor Ablation Market (2017-2032) by Type
6.2.1 Market Overview
6.2.2 Surgical Ablation
6.2.3 Percutaneous Ablation
6.2.4 Laparoscopic Ablation
6.3 Global Tumor Ablation Market (2017-2032) by Application
6.3.1 Market Overview
6.3.2 Kidney Cancer
6.3.3 Liver Cancer
6.3.4 Breast Cancer
6.3.5 Lung Cancer
6.3.6 Prostate Cancer
6.3.7 Bone Cancer
6.4 Global Tumor Ablation Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals
6.4.3 Oncology Centers
6.4.4 Others
6.5 Global Tumor Ablation Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Tumor Ablation Market (2017-2032)
7.1 North America Tumor Ablation Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Radiofrequency Ablation
7.1.3 Microwave Ablation
7.1.4 Cryoablation
7.1.5 HIFU
7.1.6 Others
7.2 North America Tumor Ablation Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Kidney Cancer
7.2.3 Liver Cancer
7.2.4 Breast Cancer
7.2.5 Lung Cancer
7.2.6 Prostate Cancer
7.2.7 Bone Cancer
7.3 North America Tumor Ablation Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Tumor Ablation Market (2017-2032)
8.1 Europe Tumor Ablation Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Radiofrequency Ablation
8.1.3 Microwave Ablation
8.1.4 Cryoablation
8.1.5 HIFU
8.1.6 Others
8.2 Europe Tumor Ablation Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Kidney Cancer
8.2.3 Liver Cancer
8.2.4 Breast Cancer
8.2.5 Lung Cancer
8.2.6 Prostate Cancer
8.2.7 Bone Cancer
8.3 Europe Tumor Ablation Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Tumor Ablation Market (2017-2032)
9.1 Asia Pacific Tumor Ablation Market (2017-2032) by Technology
9.1.1 Market Overview
9.1.2 Radiofrequency Ablation
9.1.3 Microwave Ablation
9.1.4 Cryoablation
9.1.5 HIFU
9.1.6 Others
9.2 Asia Pacific Tumor Ablation Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Kidney Cancer
9.2.3 Liver Cancer
9.2.4 Breast Cancer
9.2.5 Lung Cancer
9.2.6 Prostate Cancer
9.2.7 Bone Cancer
9.3 Asia Pacific Tumor Ablation Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Tumor Ablation Market (2017-2032)
10.1 Latin America Tumor Ablation Market (2017-2032) by Technology
10.1.1 Market Overview
10.1.2 Radiofrequency Ablation
10.1.3 Microwave Ablation
10.1.4 Cryoablation
10.1.5 HIFU
10.1.6 Others
10.2 Latin America Tumor Ablation Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Kidney Cancer
10.2.3 Liver Cancer
10.2.4 Breast Cancer
10.2.5 Lung Cancer
10.2.6 Prostate Cancer
10.2.7 Bone Cancer
10.3 Latin America Tumor Ablation Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Tumor Ablation Market (2017-2032)
11.1 Middle East and Africa Tumor Ablation Market (2017-2032) by Technology
11.1.1 Market Overview
11.1.2 Radiofrequency Ablation
11.1.3 Microwave Ablation
11.1.4 Cryoablation
11.1.5 HIFU
11.1.6 Others
11.2 Middle East and Africa Tumor Ablation Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Kidney Cancer
11.2.3 Liver Cancer
11.2.4 Breast Cancer
11.2.5 Lung Cancer
11.2.6 Prostate Cancer
11.2.7 Bone Cancer
11.3 Middle East and Africa Tumor Ablation Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Medtronic PLC
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Boston Scientific Corporation
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Johnson & Johnson
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 AngioDynamics
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 EDP TMS
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Mermaid Medical
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 CONMED Corporation
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Sonablate Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Integra Life Science Holding Corporation
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Olympus Corporation
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Smith & Nephew PLC
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
List not exhaustive
18 Global Tumor Ablation Market – Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 1.9 billion in 2023 driven by the rising prevalence and incidence of cancer across the globe.
The market is anticipated to grow at a CAGR of 14.2% during the forecast period of 2024-2032, likely to reach a market value of USD 6.3 billion by 2032.
The inclination of patients towards less invasive treatment options is fuelling the demand for the market.
One of the significant trends in the market is the surge in approvals from regulatory bodies. In March 2024, Medtronic plc received the United States FDA 510(k) approval for OsteoCool 2.0 (a bone tumor ablation system) to treat benign bone tumors and painful bone metastases.
Based on the technology, the market is segmented into radiofrequency ablation, microwave ablation, cryoablation, HIFU, and others.
Based on the type, the market is segmented into surgical ablation, percutaneous ablation, and laparoscopic ablation.
Major end users of tumor ablation include hospitals, oncology centers, and others.
Common application areas include kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and bone cancer.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Medtronic PLC, Boston Scientific Corporation, Johnson & Johnson, EDP TMS, Mermaid Medical, CONMED Corporation, Sonablate Corporation, Integra Life Science Holding Corporation, Olympus Corporation, and Smith & Nephew PLC, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER